If you have been reading about lyophilized powder and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-10-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
Lyophilized thymosin alpha-1 is generally stored at or below minus twenty degrees Celsius, protected from moisture and light. Short-term handling at ambient temperature is possible for dry powder, but reconstituted solutions degrade faster and are usually kept at two to eight degrees Celsius with a defined expiry of days rather than weeks. Repeated freeze-thaw cycles should be avoided because they promote aggregation and loss of potency. Exact limits depend on the formulation and should follow the supplier's documentation.
Identity and purity are normally assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and truncation products. Mass spectrometry confirms molecular mass and detects modifications such as deamidation or oxidation. Amino acid analysis and peptide mapping provide additional sequence-level confirmation. For research material, a certificate of analysis typically reports these results together with water content and counter-ion identity, since the lyophilized powder is often supplied as an acetate or trifluoroacetate salt.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
| Property | Value | Notes |
|---|---|---|
| Storage temperature, powder | -20 °C or lower | Protect from light and moisture |
| Storage temperature, reconstituted | 2-8 °C | Use within days |
| Purity testing | Reversed-phase HPLC | Separates truncation products |
| Mass confirmation | Mass spectrometry | Detects deamidation and oxidation |
| Common salt forms | Acetate or trifluoroacetate | Affects solubility and weighing |
The activity of this peptide is generally described as immunomodulatory rather than directly antimicrobial. Experimental work links it to signaling through certain Toll-like receptors on dendritic cells and to downstream maturation of antigen-presenting cells. Reported effects include expansion of T cell subsets, shifts in cytokine profiles, and increased natural killer cell activity. These observations come largely from cell culture and animal models, and the precise receptor-level events in humans remain incompletely characterized.
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Identity and purity are normally confirmed by reversed-phase high-performance liquid chromatography and mass spectrometry. The expected mass for the acetylated 28-residue peptide is close to 3108 daltons, and a mass shift indicates a modification or truncation. Peptide mapping after enzymatic digestion can resolve sequence-level questions. Counter-ion content, water content, and residual solvents are separate quality attributes that a certificate of analysis may or may not report. Aggregation is monitored by size-exclusion chromatography when relevant.
Thymosin alpha-1 is supplied as a lyophilized powder in most research settings. The solid dissolves readily in water and in common aqueous buffers, and it is typically reconstituted shortly before use. Solutions are clear and colourless at ordinary working concentrations. Because the peptide is hygroscopic, weighing and reconstitution are usually performed with minimal exposure to ambient air. Aliquots are prepared to avoid repeated freeze-thaw cycles, and working solutions are kept cold.
Long-term storage is generally at minus twenty degrees Celsius or colder, preferably desiccated and protected from light. Lyophilized material is more stable than reconstituted solution, which degrades faster at room temperature. Stability depends on pH, ionic strength, and the presence of oxidising agents. Published stability data for the peptide are limited, so storage claims in catalogues should be treated as general guidance rather than measured guarantees. Freeze-thaw cycles are kept to a minimum.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
In Finland, commonly eaten species include (but are not limited to) Russula vinosa, Russula vesca, Russula paludosa, Russula decolorans, Russula xerampelina and Russula claroflava. In Thailand, russulas collected by locals and sold in roadsides and local markets include Russula alboareolata, Russula lepida, Russula nigricans, Russula virescens, and Russula xerampelina. Edible russulas in Nepal include Russula flavida and Russula chlorides. The tropical Chinese species Russula griseocarnosa, misidentified as the European R. vinosa until 2009, is commercially collected as food and medicine.
=== Migraine === As of 2024, eight blockers of CGRP or its receptor have been approved by the US Food and Drug Administration for the treatment or prevention of migraine. These include erenumab, brand name Aimovig, approved in the U.S. for use for migraines in 2018. It interacts by blocking the CGRP receptor. As of 2018, fremanezumab, brand name Ajovy, was approved in the U.S. for use for migraines. It interacts with the CGRP protein expressed during an attack. Galcanezumab, brand name Emgality, was the third treatment to be approved in the U.S. in 2018 for use in migraines. It also interacts with the CGRP protein. As of February 2020, eptinezumab (Vyepti) was approved by the FDA for the treatment of migraine via intravenous infusion as well. Three small-molecule antagonists have been approved for treatment of migraine: ubrogepant, rimegepant, and atogepant. Ubrogepant and rimegepant are approved for acute treatment. Atogepant and rimegepant are approved for preventative treatment.
Confluent and reticulated papillomatosis (confluent and reticulated papillomatosis of Gougerot and Carteaud, familial cutaneous papillomatosis, familial occurrence of confluent and reticulated papillomatosis) Digitate dermatosis Drug-induced keratoderma Exfoliative dermatitis (dermatitis exfoliativa, erythroderma, red man syndrome) Florid cutaneous papillomatosis Granular parakeratosis (axillary granular parakeratosis, intertriginous granular parakeratosis) Keratolysis exfoliativa (lamellar dyshidrosis, recurrent focal palmar peeling, recurrent palmar peeling) Keratosis punctata of the palmar creases (hyperkeratosis penetrans, hyperkeratosis punctata, keratodermia punctata, keratosis punctata, keratotic pits of the palmar creases, lenticular atrophia of the palmar creases, punctate keratosis of the palmar creases) Meesmann corneal dystrophy Paraneoplastic keratoderma Pityriasis rosea (pityriasis rosea Gibert) Pityriasis rubra pilaris (Devergie's disease, lichen ruber acuminatus, lichen ruber pilaris) Pure hair-nail type ectodermal dysplasia Small plaque parapsoriasis (chronic superficial dermatitis) Tripe palms Xanthoerythrodermia perstans
Genetic defects in the creatine biosynthetic pathway enzymes lead to various severe neurological defects. Defects in the two synthesis enzymes cause L-arginine:glycine amidinotransferase deficiency and guanidinoacetate methyltransferase deficiency. Both biosynthetic defects are inherited in an autosomal recessive manner. Creatine transporter defect, characterized by insufficient transport of creatine to the brain, is caused by mutations in SLC6A8 and is inherited in an X-linked manner.
Sources: en.wikipedia.org
== Animal studies == Like tropoflavin, administration of R7 has been found to activate the TrkB in vivo in the mouse brain. Moreover, R7 was found to potently activate the TrkB and the downstream Akt signaling pathway upon oral administration, an action that was tightly correlated with plasma concentrations of tropoflavin. As such, R7 has shown in vivo efficacy as an agonist of the TrkB, including central activity, similarly to tropoflavin.
In February 2020, bempedoic acid was approved for use in the United States both as a standalone drug (brand name Nexletol) and in a fixed-dose combination with ezetimibe (brand name Nexlizet). The U.S. Food and Drug Administration (FDA) granted the approval of Nexletol to Esperion Therapeutics. The FDA approved bempedoic acid based on evidence from two clinical trials (Trial 1/ NCT02666664 and Trial 2/NCT02991118) of 3009 subjects with high LDL cholesterol and known atherosclerotic cardiovascular disease or HeFH. The trials were conducted in United States, Canada, and Europe.
Uranium-238 is predominantly an alpha emitter, decaying to thorium-234. It ultimately decays through the uranium series, which has 18 members, into lead-206. Uranium-238 is not fissile, but is a fertile isotope, because after neutron activation it can be converted to plutonium-239, another fissile isotope. Indeed, the 238U nucleus can absorb one neutron to produce the radioactive isotope uranium-239. 239U decays by beta emission to neptunium-239, also a beta-emitter, that decays in its turn, within a few days into plutonium-239. 239Pu was used as fissile material in the first atomic bomb detonated in the "Trinity test" on 16 July 1945 in New Mexico. Uranium-235 has a half-life of about 7.04×108 years; it is the next most stable uranium isotope after 238U and is also predominantly an alpha emitter, decaying to thorium-231. Uranium-235 is important for both nuclear reactors and nuclear weapons, because it is the only uranium isotope existing in nature on Earth in significant amounts that is fissile. This means that it can be split into two or three fragments (fission products) by thermal neutrons. The decay chain of 235U, which is called the actinium series, has 15 members and eventually decays into lead-207. The constant rates of decay in these decay series makes the comparison of the ratios of parent to daughter elements useful in radiometric dating. Uranium-236 has a half-life of 2.342×107 years and is not found in significant quantities in nature.
Sources: en.wikipedia.org
To diagnose LMS, a physical exam may be performed by one's physician, imaging tests such as MRI, CT, and PET scans can be performed, or tissue biopsies can also be completed where the histopathology of the removed tissue sample is examined.
== External links == Countercurrent multiplier animation from Colorado University. Research about elephant seals using countercurrent heat exchange to keep heat from leaving their body while breathing out, during hibernation. Patent for a snow mask with a removable countercurrent exchange module which keeps the warmth from leaving the mask when breathing out.
Shulman (1943), biophysicist, Sterling Professor emeritus at Yale University Seymour Jonathan Singer (1943), cell biologist and professor at the University of California, San Diego Enoch Callaway (1943), psychiatrist, professor at the University of California, San Francisco Arnold Cooper (1944), psychoanalyst; professor at Weill Cornell Medical College and former president of the American Psychoanalytic Association Robert Jastrow (1944), astronomer, founder of NASA's Goddard Institute for Space Studies and conservative think tank George C. Marshall Institute Joshua Lederberg (1944), winner of the Nobel Prize in Physiology or Medicine Arnold Scheibel (1944), professor of neuroscience at the University of California, Los Angeles Alfred P. Wolf (1944), nuclear and organic chemist; research professor at New York University Paul Marks (1945), geneticist, president emeritus of the Memorial Sloan Kettering Cancer Center, former editor-in-chief of the Journal of Clinical Investigation Jack Oliver (1945), professor of seismology at Columbia University and Cornell University Malvin Ruderman (1945), physicist known for discovering the RKKY interaction Leonard Shengold (1946), psychiatrist at New York University known for study on child abuse Albert Starr (1946), cardiovascular surgeon, winner of the 2007 Lasker Award Arthur Ashkin (1947), winner of the Nobel Prize in Physics in 2018 Robert A. Frosch (1947), fifth administrator of the National Aeronautics and Space Administration Norton Zinder (1947), scientist who discovered bacterial transduction Frank I.
In 2024, SIUT acquired a four-star Pakistani hotel, Regent Plaza Hotel, to convert it into a health care facility. The Regent Plaza hotel was located on Shahrah-e-Faisal, consisting an plot area of 13,200 square yards, with construction having a total covered area of 47,034 square yards. SIUT acquired the Regent Plaza from Pakistan Hotels Developers Limited for PKR 14.5 billion.
Sources: en.wikipedia.org
Dry lyophilized powder tolerates short ambient exposure during handling and shipping. Long-term room-temperature storage is not recommended because moisture uptake and slow degradation can occur over months. Storage at minus twenty degrees Celsius is the common practice for extended periods.
Typical entries list appearance, identity by mass spectrometry, purity by chromatography, water or moisture content, and residual counter-ion. Some certificates also report microbial limits and endotoxin for materials intended for laboratory use. The reported methods and acceptance ranges vary between suppliers.
The peptide is often supplied as an acetate or trifluoroacetate salt, and the counter-ion affects solubility, weight-per-mole calculations, and compatibility with cell assays. Trifluoroacetate can be undesirable in some biological experiments. Knowing the salt form is necessary for accurate concentration determination.
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.